Breaking News Instant updates and real-time market news.

MESO

Mesoblast

$4.29

0.03 (0.70%)

06:08
10/06/16
10/06
06:08
10/06/16
06:08

Mesoblast publishes Phase 2 trial results of cell therapy for kidney disease

Mesoblast announced results from the randomized, placebo-controlled Phase 2 trial of its proprietary allogeneic Mesenchymal Precursor Cell product candidate, MPC-300-IV, in patients with diabetic kidney disease, published in the current issue of the peer-reviewed journal EBioMedicine. The paper concluded that a single intravenous infusion of MPC-300-IV was well tolerated and had positive effects on renal function at the 12-week primary endpoint in a Phase 2 trial in adult patients with type 2 diabetic nephropathy. The Phase 2, double-blind, randomized, placebo-controlled, dose-escalating trial evaluated MPC-300-IV in patients with type 2 diabetes and moderate to severe renal impairment, stage 3b-4 chronic kidney disease, who were already on a stable regimen of the standard of care therapy for diabetic nephropathy. Safety profile for MPC-300-IV treatment was similar to placebo, with no treatment-related adverse events. Efficacy testing showed that patients receiving a single MPC infusion at either dose had improved renal function relative to placebo.

MESO Mesoblast
$4.29

0.03 (0.70%)

02/19/16
CHDN
02/19/16
INITIATION
Target $5.5
CHDN
Neutral
Mesoblast initiated with a Neutral at Chardan
Target $5.50.
03/07/16
JPMS
03/07/16
DOWNGRADE
Target $10
JPMS
Neutral
Mesoblast downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Mesoblast to Neutral citing the 44% year-to-date rise in the shares. The analyst has a $10 price target for the name.
06/14/16
FBCO
06/14/16
DOWNGRADE
Target $5
FBCO
Neutral
Mesoblast downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Alethia Young downgraded Mesoblast (MESO) to Neutral citing caution following the company's break-up with Teva (TEVA). Mesoblast should be able to find a new partner for its chronic heart failure program, but it could take some time, Young tells investors in a research note. She lowered her probability of success for the program to 25% from 40%. The analyst halved her price target for Mesoblast shares to $5 from $10. The shares have been halted since May 31, when they closed at $7.07.
06/15/16
JPMS
06/15/16
NO CHANGE
JPMS
Neutral
JPMorgan still cautious on Mesoblast, removes price target
JPMorgan analyst Anupam Rama says he remains cautious on Mesoblast (MESO) shares post the company's update related to MPC-150-IM in chronic heart failure. There are still some open questions following the two week trading halt, including why Teva (TEVA) has backed out following an interim data monitoring committee assessment and after committing resources to the program. The analyst sees growing concerns related to management credibility and removed his $10 price target for the stock. He keeps a Neutral rating on Mesoblast.

TODAY'S FREE FLY STORIES

CEQP

Crestwood Equity

$26.40

-0.6 (-2.22%)

07:05
02/21/17
02/21
07:05
02/21/17
07:05
Earnings
Crestwood Equity reports Q4 EPS ($1.20), may not compare to consensus 16c »

Reports Q4 revenue $795M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 02

    Mar

MDT

Medtronic

$78.88

0.89 (1.14%)

07:05
02/21/17
02/21
07:05
02/21/17
07:05
Earnings
Medtronic backs FY17 EPS $4.55-$460, consensus $4.56 »

The company continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 27

    Feb

  • 07

    Mar

  • 17

    Mar

  • 21

    Mar

WMT

Wal-Mart

$69.37

0.5 (0.73%)

07:05
02/21/17
02/21
07:05
02/21/17
07:05
Earnings
Wal-Mart sees Q1 EPS of 90c-$1.00, consensus 96c »

For the 13-week period…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

XCRA

Xcerra

$8.30

0.13 (1.59%)

07:04
02/21/17
02/21
07:04
02/21/17
07:04
Earnings
Xcerra sees Q3 non-GAAP EPS 10c-14c, consensus 8c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TREX

Trex Company

$69.81

-0.76 (-1.08%)

07:04
02/21/17
02/21
07:04
02/21/17
07:04
Earnings
Trex Company sees Q1 net sales approx. $144M, consensus $143.28M »

Incremental gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

WMT

Wal-Mart

$69.37

0.5 (0.73%)

07:04
02/21/17
02/21
07:04
02/21/17
07:04
Earnings
Wal-Mart reports Q4 adjusted EPS $1.30, consensus $1.29 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

TREX

Trex Company

$69.81

-0.76 (-1.08%)

07:03
02/21/17
02/21
07:03
02/21/17
07:03
Hot Stocks
Trex Company board approves new 2.96M share repurchase program »

The Company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

TREX

Trex Company

$69.81

-0.76 (-1.08%)

07:03
02/21/17
02/21
07:03
02/21/17
07:03
Earnings
Trex Company reports Q4 EPS 43c, consensus 41c »

Reports Q4 revenue $95M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

XCRA

Xcerra

$8.30

0.13 (1.59%)

07:02
02/21/17
02/21
07:02
02/21/17
07:02
Earnings
Xcerra reports Q2 non-GAAP EPS 6c, consensus (2c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$61.65

-0.14 (-0.23%)

07:01
02/21/17
02/21
07:01
02/21/17
07:01
Hot Stocks
Six Flags signs agreement to build Six Flags-branded parks at second China site »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

INOV

Inovalon

$11.30

-0.45 (-3.83%)

07:01
02/21/17
02/21
07:01
02/21/17
07:01
Recommendations
Inovalon analyst commentary  »

Piper sees lawsuit as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SRPT

Sarepta

$28.28

0.31 (1.11%)

07:00
02/21/17
02/21
07:00
02/21/17
07:00
Hot Stocks
Sarepta agrees to sale of priority review voucher for $125M »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

SEAS

SeaWorld

$19.21

-0.03 (-0.16%)

07:00
02/21/17
02/21
07:00
02/21/17
07:00
Earnings
Breaking Earnings news story on SeaWorld »

SeaWorld reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TVPT

Travelport

$14.14

-0.06 (-0.42%)

06:58
02/21/17
02/21
06:58
02/21/17
06:58
Earnings
Travelport reports Q4 adjusted EPS 23c, consensus 20c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

MDT

Medtronic

$78.88

0.89 (1.14%)

06:58
02/21/17
02/21
06:58
02/21/17
06:58
Earnings
Medtronic reports Q3 EPS $1.12, consensus $1.11 »

Reports Q3 revenue $7.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 27

    Feb

  • 07

    Mar

  • 17

    Mar

  • 21

    Mar

REXR

Rexford Industrial

$22.92

0.24 (1.06%)

06:57
02/21/17
02/21
06:57
02/21/17
06:57
Hot Stocks
Rexford Industrial acquires industrial property in Los Angeles for $17.1M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOXO

Loxo Oncology

$41.74

0.36 (0.87%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Hot Stocks
Loxo Oncology completes enrollment for larotrectinib NDA »

Loxo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$30.37

-0.08 (-0.26%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Periodicals
GE succession plan near top of investors' minds, WSJ says »

General Electric CEO Jeff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Apr

JELD

JELD-WEN Holding

$29.48

0.48 (1.66%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVN

Trevena

$7.13

0.1 (1.42%)

06:55
02/21/17
02/21
06:55
02/21/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Trevena »

Trevena trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 21

    Mar

TIF

Tiffany

$86.18

3.17 (3.82%)

06:54
02/21/17
02/21
06:54
02/21/17
06:54
Hot Stocks
Tiffany, JANA Partners announce agreement to appoint 3 new independent directors »

Tiffany and JANA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

$16.73

0.11 (0.66%)

06:54
02/21/17
02/21
06:54
02/21/17
06:54
Hot Stocks
Breaking Hot Stocks news story on Enable Midstream »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ENBL

Enable Midstream

$16.73

0.11 (0.66%)

06:53
02/21/17
02/21
06:53
02/21/17
06:53
Earnings
Enable Midstream reports Q4 EPS 14c, consensus 18c »

Reports Q4 revenue $614M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

WLK

Westlake Chemical

$61.66

-0.99 (-1.58%)

06:51
02/21/17
02/21
06:51
02/21/17
06:51
Earnings
Westlake Chemical reports Q4 EPS 76c with items, consensus 80c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

JNCE

Jounce Therapeutics

$19.90

0.24 (1.22%)

06:51
02/21/17
02/21
06:51
02/21/17
06:51
Initiation
Jounce Therapeutics initiated  »

Jounce Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.